Paper19436622
Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
Ricci F and 3 others. Ther Clin Risk Manag, 2009. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Papers, record 19436622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19436622
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References110
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14586480 | Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. | Leukemia | 2004 | https://conductscience.org/library/papers/14586480 | PubMed |
| 2 | 16131571 | Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. | Blood | 2005 | https://conductscience.org/library/papers/16131571 | PubMed |
| 3 | 3478543 | Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. | Leukemia | 1987 | https://conductscience.org/library/papers/3478543 | PubMed |
| 4 | 15071604 | Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). | Leukemia | 2004 | https://conductscience.org/library/papers/15071604 | PubMed |
| 5 | 10334546 | Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10334546 | PubMed |
| 6 | 15197800 | Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. | Cancer | 2004 | https://conductscience.org/library/papers/15197800 | PubMed |
| 7 | 3807892 | Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. | Mol Pharmacol | 1987 | https://conductscience.org/library/papers/3807892 | PubMed |
| 8 | 1675805 | Metabolism and action of purine nucleoside analogs. | Pharmacol Ther | 1991 | https://conductscience.org/library/papers/1675805 | PubMed |
| 9 | 11436116 | Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. | Bone Marrow Transplant | 2001 | https://conductscience.org/library/papers/11436116 | PubMed |
| 10 | 15117764 | Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. | Blood | 2005 | https://conductscience.org/library/papers/15117764 | PubMed |
| 11 | 10779422 | Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. | Blood | 2000 | https://conductscience.org/library/papers/10779422 | PubMed |
| 12 | 11114313 | Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. | N Engl J Med | 2000 | https://conductscience.org/library/papers/11114313 | PubMed |
| 13 | 9753416 | First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. | Eur J Haematol | 1998 | https://conductscience.org/library/papers/9753416 | PubMed |
| 14 | 19704063 | Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19704063 | PubMed |
| 15 | 9694704 | Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. | Blood | 1998 | https://conductscience.org/library/papers/9694704 | PubMed |
| 16 | 11529853 | Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. | Br J Haematol | 2001 | https://conductscience.org/library/papers/11529853 | PubMed |
| 17 | 18710390 | High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. | Br J Haematol | 2008 | https://conductscience.org/library/papers/18710390 | PubMed |
| 18 | 3050447 | Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. | Mol Pharmacol | 1988 | https://conductscience.org/library/papers/3050447 | PubMed |
| 19 | 11920267 | The bioavailability of oral fludarabine phosphate is unaffected by food. | Hematol J | 2001 | https://conductscience.org/library/papers/11920267 | PubMed |
| 20 | 7042080 | Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. | Cancer Res | 1982 | https://conductscience.org/library/papers/7042080 | PubMed |
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42615647 | Activity of MMV Pandemic Response Box compounds against Mycobacterium ulcerans viability and mycolactone production. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42615647 | PubMed |
| 41697742 | PDGFRβ signaling restrains myocyte function to limit the regenerative capacity of skeletal muscle. | J Clin Invest | 2026 | https://conductscience.org/library/papers/41697742 | PubMed |
| 40649226 | Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions. | Molecules | 2025 | https://conductscience.org/library/papers/40649226 | PubMed |
| 40430552 | 5'-Guanidino Xylofuranosyl Nucleosides as Novel Types of 5'-Functionalized Nucleosides with Biological Potential. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430552 | PubMed |
| 40336064 | Fludarabine attenuates inflammation and dysregulated autophagy in alveolar macrophages via inhibition of STAT1/IRF1 pathway. | Lab Anim Res | 2025 | https://conductscience.org/library/papers/40336064 | PubMed |
| 40176969 | 3'-O-β-Glucosylation of nucleoside analogues using a promiscuous bacterial glycosyltransferase. | RSC Chem Biol | 2025 | https://conductscience.org/library/papers/40176969 | PubMed |
| 38893081 | Skin Malignancies Due to Anti-Cancer Therapies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893081 | PubMed |
| 38775157 | BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia. | JCI Insight | 2024 | https://conductscience.org/library/papers/38775157 | PubMed |
| 38279745 | Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation. | Curr Top Med Chem | 2024 | https://conductscience.org/library/papers/38279745 | PubMed |
| 38140557 | The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic. | Viruses | 2023 | https://conductscience.org/library/papers/38140557 | PubMed |
| 37397557 | Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. | Genes Dis | 2023 | https://conductscience.org/library/papers/37397557 | PubMed |
| 37226709 | Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia. | Haematologica | 2023 | https://conductscience.org/library/papers/37226709 | PubMed |
| 37002214 | Age-dependent Pdgfrβ signaling drives adipocyte progenitor dysfunction to alter the beige adipogenic niche in male mice. | Nat Commun | 2023 | https://conductscience.org/library/papers/37002214 | PubMed |
| 35358273 | Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia. | PLoS One | 2022 | https://conductscience.org/library/papers/35358273 | PubMed |
| 35323219 | Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells. | Med Sci (Basel) | 2022 | https://conductscience.org/library/papers/35323219 | PubMed |
| 35280986 | Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation. | Front Immunol | 2022 | https://conductscience.org/library/papers/35280986 | PubMed |
| 33657175 | Inhibition of innate immune response ameliorates Zika virus-induced neurogenesis deficit in human neural stem cells. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/33657175 | PubMed |
| 32560115 | Discovery of Anti-Amoebic Inhibitors from Screening the MMV Pandemic Response Box on Balamuthia mandrillaris, Naegleria fowleri, and Acanthamoeba castellanii. | Pathogens | 2020 | https://conductscience.org/library/papers/32560115 | PubMed |
| 29789639 | Fludarabine and neurotoxicity in engineered T-cell therapy. | Gene Ther | 2018 | https://conductscience.org/library/papers/29789639 | PubMed |
| 29317636 | The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29317636 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19436622
GET https://conductscience.org/api/papers/v1/19436622/references?page=2